Skip to main content

Table 1 Study characteristics of the included studies. ALP activity: alkaline phosphatase activity, SrHA: strontium hydroxyapatite, and ZOLHA (zoledronate hydroxyapatite), BMP-2: bone morphogenetic protein 2

From: Effect of bisphosphonate treatment of titanium surfaces on alkaline phosphatase activity in osteoblasts: a systematic review and meta-analysis

Study ID Year Sample size per experiment Time point of measurement Cell type Type of bisphosphonate Amount / concentration ALP activity (3 days) ALP activity (4 days) ALP activity (7 days) ALP activity (10 days) ALP activity (14 days) ALP activity (18 days) ALP activity (21 days) Coating specificaiton
Bigi et al. [40] 2009 3 7, 14 days MG-63 osteoblast like cells Control    2.17 ± 1.21   4.81 ± 0.27    Hydroxyapatite
Bigi et al. [40] 2009 3 7, 14 days MG-63 osteoblast like cells Alendronate 7 mM    2.12 ± 0.20   4.72 ± 0.08    Hydroxyapatite
Bigi et al. [40] 2009 3 7, 14 days MG-63 osteoblast like cells Alendronate 28 mM    2.29 ± 0.45   5.23 ± 0.14    Hydroxyapatite
Boanini et al. [41] 2015 6 10, 21 days MG-63 osteoblast like cells Control     0.82 ± 0.12    0.99 ± 0.12 Strontium-substituted hydroxyapatite (SrHA)
Boanini et al. [41] 2015 6 10, 21 days MG-63 osteoblast like cells Zoledronat Gradient composition C2 (SrHA and ZOLHA)     1 ± 0.15    1.09 ± 0.08 Strontium-substituted hydroxyapatite (SrHA)
Boanini et al. [41] 2015 6 10, 21 days MG-63 osteoblast like cells Zoledronat Gradient composition C3 (SrHA and ZOLHA)     0.79 ± 0.1    0.92 ± 0.08 Strontium-substituted hydroxyapatite (SrHA)
Boanini et al. [41] 2015 6 10, 21 days MG-63 osteoblast like cells Zoledronat Gradient composition C4 (SrHA and ZOLHA)     0.75 ± 0,1    0.86 ± 0.16 Strontium-substituted hydroxyapatite (SrHA)
Boanini et al. [41] 2015 6 10, 21 days MG-63 osteoblast like cells Zoledronat ZOLHA     0,80 ± 0.06    0.92 ± 0,15 Strontium-substituted hydroxyapatite (SrHA)
Boanini et al. [42] 2015 6 14 days Osteoblast derived from stem cells Control      10.6 ± 2.1    Octacalcium phosphate
Boanini et al. [42] 2015 6 14 days Osteoblast derived from stem cells Alendronate 8 mM      16.3 ± 2.6    Octacalcium phosphate
Boanini et al. [42] 2015 6 14 days Osteoblast derived from stem cells Alendronate 20 mM      9.63 ± 2.30    Octacalcium phosphate
Hu et al. [44] 2013 5 14 days MC3T3-E1 Control      0.41 ± 0.02    Precoated hydroxyapatite (CaP) layer
Hu et al. [44] 2013 5 14 days MC3T3-E1 Alendronate 0.2 mg/ml solution      0.57 ± 0.04    Precoated hydroxyapatite (CaP) layer
Hu et al. [44] 2013 5 14 days MC3T3-E1 Alendronate 0.5 mg/ml solution      0.59 ± 0.04    Precoated hydroxyapatite (CaP) layer
Hu et al. [44] 2013 5 14 days MC3T3-E1 Alendronate 1 mg/ml solution      0.59 ± 0.63    Precoated hydroxyapatite (CaP) layer
Jeon et al [43] 2019 5 3 days MG-63 osteoblast like cells Control 1.11 ± 0.09        UV treatment
Jeon et al [43] 2019 5 3 days MG-63 osteoblast like cells Alendronate 10−3 M 1.16 ± 0.17        UV treatment
Kim et al. [45] 2013 5 7, 14, 21 days MG-63 osteoblast like cells Control    1.12 ± 0.03   3.44 ± 0.14   4.01 ± 0.09 Heparin-coated
Kim et al. [45] 2013 5 7, 14, 21 days MG-63 osteoblast like cells Alendronate 1 mg/ml solution    1.19 ± 0.04   5.29 ± 0.06   4.41 ± 0.12 Heparin-coated
Kim et al. [45] 2013 5 7, 14, 21 days MG-63 osteoblast like cells Control    1.31 ± 0.05   5.86 ± 0.23   4.65 ± 0.13 BMP-2/Heparin-coated
Kim et al. [45] 2013 5 7, 14, 21 days MG-63 osteoblast like cells Alendronate 1 mg/ml solution    1.41 ± 0.04   6.65 ± 0.27   5.36 ± 0.13 BMP-2/Heparin-coated
Kim et al. [46] 2017 3 7 days MG-63 osteoblast like cells Control    1.49 ± 0.23      without UV treatment
Kim et al. [46] 2017 3 7 days MG-63 osteoblast like cells Alendronate 10−6 M    4.08 ± 0.23      without UV treatment
Kim et al. [46] 2017 3 7 days MG-63 osteoblast like cells Control    3.49 ± 0.34      with UV treatment
Kim et al. [46] 2017 3 7 days MG-63 osteoblast like cells Alendronate 10−6 M    6.22 ± 0.78      with UV treatment
Moon et al. [47] 2011 3 7, 14, 21 days MC3T3-E1 Control    2.56 ± 0.17   3.60 ± 0.06   3.48 ± 0.13 Heparin-coated
Moon et al. [47] 2011 3 7, 14, 21 days MC3T3-E1 Alendronate 1 mg    3.55 ± 0.10   5.35 ± 0.17   4.36 ± 0.11 Heparin-coated
Moon et al. [47] 2011 3 7, 14, 21 days MC3T3-E1 Alendronate 5 mg    4.24 ± 0.29   7.80 ± 0.21   5.35 ± 0.15 Heparin-coated
Mu et al. [48] 2018 5 7 days Osteoblasts from neonate rat calvaria Control    0.53 ± 0.05      Hyaluronan
Mu et al. [48] 2018 5 7 days Osteoblasts from neonate rat calvaria Alendronate 500 mg    0.63 ± 0.06      Hyaluronan
Yoshinari et al. [49] 2000 6 7 days Osteoblastic cells from calvariae of Sprague-Dawley rats Control    51.7 ± 5.9      Hydroxyapatite
Yoshinari et al. [49] 2000 6 7 days Osteoblastic cells from calvariae of Sprague-Dawley rats Pamidronate disodium 10−2 M    65.4 ± 9.7      Hydroxyapatite
Zheng et al. [50] 2016 3 4,7,10,14,18 days MC3T3-E1 Control   1.19 ± 0.15 1.81 ± 0.20 3.27 ± 0,38 3.30 ± 0.27 2.66 ± 0.25   Plasma treated titanium
Zheng et al. [50] 2016 3 4,7,10,14,18 days MC3T3-E1 Alendronate 2.5 mg/ml solution   1.59 ± 0.13 2.36 ± 0.27 3.58 ± 0.20 3.66 ± 0.28 2.65 ± 0.25   Plasma treated titanium
Zheng et al. [50] 2016 3 4,7,10,14,18 days MC3T3-E1 Control   1.20 ± 0.16 1.95 ± 0,26 3.26 ± 0.16 3,3 ± 0.13 2.62 ± 0.36   Plasma treated, silane-treated
Zheng et al. [50] 2016 3 4,7,10,14,18 days MC3T3-E1 Alendronate 0.5 mg/ml solution   1.52 ± 0.16 2.66 ± 0,16 3.93 ± 0.26 4.32 ± 0.30 3.18 ± 0.24   Plasma treated, silane-treated
Zheng et al. [50] 2016 3 4,7,10,14,18 days MC3T3-E1 Alendronate 1 mg/ml solution   1.62 ± 0.12 3.39 ± 0,23 4.99 ± 0.28 3.70 ± 0.13 3.05 ± 0.14   Plasma treated, silane-treated